Pharsight

Drugs that contain Alogliptin Benzoate

1. List of Nesina drug patents

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 9 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(2 years from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(6 years from now)

Do you want to check out NESINA patents from before 2022?

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

How can I launch a generic of NESINA before it's patent expiration?
More Information on Dosage

NESINA family patents

12

United States

8

China

6

Japan

3

Argentina

3

Taiwan

2

Spain

2

Canada

2

Norway

2

Croatia

2

Korea, Republic of

2

Israel

2

European Union

1

Hong Kong

1

Austria

1

Malaysia

1

Denmark

1

RS

1

Germany

1

Poland

1

Brazil

1

Ukraine

1

Morocco

EA

1

EA

1

New Zealand

1

Cyprus

1

Peru

1

Chile

1

Portugal

1

Georgia

1

Mexico

1

Australia

1

Costa Rica

1

Netherlands

1

South Africa

1

Luxembourg

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic